Disease Information & Support


The Word:


Generic name Vincristine sulfate liposome injection
Pronunciation vin-KRIS-teen SUHL-feyt
Brand name(s), other common name(s) Marqibo®
Drug type  Antimitotic 
How the drug is given Intravenously (IV) (fatal if given by other routes)

Vincristine sulfate liposome injection is FDA approved for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.

Side effects needing medical attention: Constipation; bowel obstruction; nausea; fever; fatigue; diarrhea; decreased appetite; insomnia; low blood cell counts; pneumonia; life-threatening low blood pressure; infection; peripheral sensory and motor neuropathy; lack of strength; muscular weakness; respiratory distress; respiratory failure; pain; abdominal pain; hypotension; mental status changes; cardiac arrest.


For information on how to manage the costs of drug therapy, please see Financial Matters and Prescription Drug Coverage, or to speak with an Information Specialist, call (800) 955-4572.

last updated on Tuesday, October 16, 2012